Johnson & Johnson Received FDA Approval for TRUFILL n BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
On December 18, 2025, Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S. Food and Drug Administration (FDA) had approved an expanded indication for the TRUFILL n-BCA Liquid Embolic System for embolization of the middle meningeal artery (MMA) as an adjunct to surgery in the treatment of symptomatic subacute and chronic subdural hematoma (cSDH).
At the time, cSDH was commonly associated with minor head trauma that resulted in bleeding between the dura and arachnoid membranes, particularly...